tbuckley/cabot-search huggingface dataset:
Pain and Sedation Scales for Neonatal and Pediatric Patients in a Preverbal Stage of Development
Authors: Vito Giordano, Joy Edobor, Philipp Deindl, Brigitte Wildner, Katharina Goeral, Philipp Steinbauer, Tobias Werther, Angelika Berger, Monika Olischar
Journal: JAMA Pediatrics (2019)

Because children in a preverbal stage of development are unable to voice their feelings, they completely depend on their caregiving team for the interpretation and management of their pain and discomfort. Thus, accurately validated scales to assess pain and sedation levels are crucial.To provide clinicians a complete overview on the validity and reliability of the existing pain and sedation scales for different target populations (preterm infants, term infants, and toddlers) and in different clinical contexts.BIOSIS Previews, Cumulative Index to Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Embase, MEDLINE, PsycCRITIQUES, PsycINFO, PSYNDEXplus Literature and Audiovisual Media, and PSYNDEXplus Tests were the databases screened from their inception to August 2018. All studies examining the validity or reliability of a given pain or sedation scale for patients in a preverbal stage of development were included in this systematic review. Those scales that were tested for at least construct validity, internal consistency, and interrater reliability were subsequently scored using the consensus-based standards for the selection of health measurement instruments (COSMIN) checklist.In total, 89 validation articles comprising 65 scales were included. Fifty-seven scales (88%) were useful for assessing pain, 13 scales (20%) for assessing sedation, and 4 scales (6%) for assessing both conditions. Forty-two (65%) were behavioral scales, and 23 (35%) were multidimensional scales. Eleven scales (17%) were validated for infants on mechanical ventilation. Thirty-seven scales (57%) were validated for preterm infants, 24 scales (37%) for term and preterm infants, 7 scales (11%) for term-born children, 7 scales (11%) for preterm infants, term infants, and toddlers, and 17 scales (26%) for term infants and toddlers. Twenty-eight scales (43%) considered construct validity, internal consistency, and interrater reliability.Clinicians should consider using scales that are validated for at least construct validity, internal consistency, and interrater reliability, combining this information with the population of interest and the construct the scale is intended to measure.
Multicentre study of perfusion magnetic resonance imaging in paediatric brain tumours
Authors: Stephanie Withey, Lesley MacPherson, Adam Oates, Stephen Powell, Jan Novak, Laurence Abernethy, Barry Pizer, Richard Grundy, Simon Bailey, Dipayan Mitra, Theodoros Arvanitis, Dorothee Auer, Shivaram Avula, Andrew Peet
Journal: Neuro-Oncology (2019)

Abstract Studies in adults have shown that brain tumour perfusion correlates with grade. These studies are dominated by gliomas grade II to IV which are rare in children. The standard method, Dynamic Susceptibility Contrast MRI, provides estimates of relative cerebral blood volume (rCBV) but contrast agent leakage affects rCBV accuracy. The majority of perfusion studies have been conducted at single centres and variation in acquisition protocols makes the generalizability of results questionable. The aim of this study was to compare leakage-corrected rCBV with grade in paediatric brain tumours at multiple centres. Scans were analysed from 85 patients at 4 centres on 6 scanners prior to treatment. MRI protocols varied between centres. Histological diagnoses including grade were obtained. Whole-tumour median rCBV was significantly higher in the 45 high grade than the 40 low grade tumours (2.54 ± 1.63 ml/100ml vs 1.68 ± 1.36 ml/100ml, p=0.010). Low grade tumours, particularly pilocytic astrocytomas (grade I), displayed more contrast agent leakage consistent with their appearance on contrast enhanced images and required more leakage correction than high grade tumours. This finding differs from that in adults where contrast agent uptake is usually associated with higher grade. A cut-off of 1.70 ml/100ml for rCBV gave sensitivity and specificity of 76% and 65% respectively for discriminating grade. In summary, perfusion MRI can be used to help distinguish between low and high grade paediatric brain tumours. This finding is robust across multiple centres and acquisition protocols but correction should be made for leakage of contrast agent from the vessels.
A Modified Glasgow Prognostic Score (mGPS) Based On Systemic Inflammatory Response Is a Useful Indicator to Predict Response and Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Authors: Sung-Hoon Jung, Deok-Hwan Yang, Jae-Sook Ahn, Yeo-Kyeoung Kim, Hyeoung-Joon Kim, Je-Jung Lee
Journal: Blood (2012)
Potent In Vivo Anti-Tumor Activity Of Extracellular Vesicles Isolated From Genetically Engineered Primary Mesenchymal Stromal Cells Expressing The Trans-Membrane TNF-Related Apoptosis-Inducing Ligand (TRAIL)
Authors: Stefano Buttiglieri, Carmelo Carlo-Stella, Tiziana Spatola, Roberta Pulito, Luigi Naldini, Andrea Anichini, Michele Magni, Arianna Giacomini, Corrado Tarella, Alessandro M. Gianni
Journal: Blood (2013)
Elevated Labile Plasma Iron Levels (LPI) and Increased Oxidative Stress Are Associated with Red Blood Cell Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Subtitle: from the European Leukemianet MDS Registry
Authors: Marlijn Hoeks, Saskia Langemeijer, Louise De Swart, Tim Bagguley, Corine van Marrewijk, David Bowen, Jaroslav Cermak, Eva Hellstrom-Lindberg, Aurelia Tatic, Argiris Symeonidis, Marian G.J. Van Kraaij, Panagiotis Panagiotidis, Hege Garelius, Dominic J Culligan, Marta Krejci, Jackie Droste, Alexandra Smith, Dorine W. Swinkels, Theo de Witte
Journal: Blood (2016)
Clinical Characteristics of Autosomal Dominat Giant Platelet Syndromes (GPS) and Mutation Analysis of MYH9 Encoding Non-Muscle Myosin Heavy Chain from 6 Unrelated Korean Patients.
Authors: Hoon Kook, Jung Mi Yang, Hae Jin Kee, Gwang Hyeon Eom, Hee Jo Baek, Tai Ju Hwang, Duck Cho, Myung-Geun Shin, Je Jung Lee, Hyeoung Joon Kim, Jun-Hyuk Lee, Soo Hyun Eom, Hyun Kook
Journal: Blood (2005)
A Proteasome Specific Binding Assay for Quantitation of Constitutive and Immunoproteasome Active Sites.
Authors: Mark K. Bennett, Monette A. Aujay, Tonia J. Buchholz, Susan D. Demo, Guy J. Laidig, Congcong M. Sun, Marcy K. Vallone, Tina Woo, Mark S. Smyth
Journal: Blood (2005)
Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial
Authors: Kai Neben, Henk M. Lokhorst, Anna Jauch, Uta Bertsch, Thomas Hielscher, Christiane Heiss, Bronno van der Holt, Stefan Schmitt, Laila el Jarari, Hans J. Salwender, Igor W. Blau, Michael Pfreundschuh, Katja Weisel, Ulrich Duehrsen, Walter Lindemann, Christian Teschendorf, Hans Martin, Christof Scheid, Mathias Haenel, Hans Guenter Derigs, Ullrich Graeven, Ingo GH Schmidt-Wolf, Norma Peter, Mohammed Wattad, Steffen P Luntz, Annemiek Broyl, Joerg Schubert, Martin Hoffmann, Martin Goerner, Jochen Tischler, Martin Kaufmann, Marc S Raab, Anthony D. Ho, Helgi van de Velde, Dirk Hose, Pieter Sonneveld, Hartmut Goldschmidt
Journal: Blood (2011)
The Association of a Salvage Treatment Containing Novel Agents Followed by Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning Regimen Improves Overall Survival and Time-to-Progression in Multiple Myeloma Patiens Relapsing After Autologous Stem Cell Transplantation: A Multicentric Retrospective Study Based On Donor Availability.
Authors: Francesca Patriarca, Hermann Einsele, Francesco Spina, Chiara Nozzoli, Andrea Nozza, Alessandra Sperotto, Fortunato Morabito, Gernot Stuhler, Stefan Knop, Michela Cerno, Alberto Bosi, Renato Fanin, Paolo Corradini
Journal: Blood (2009)
Activity of the Histone Deacetylase (HDAC) Inhibitor PXD101 in Preclinical Studies and in a Phase I Study in Patients with Advanced Haematological Tumors.
Authors: Peter Gimsing, Frank Wu, Xiaozhong Qian, Michael Jeffers, Lene Knudsen, Maxwell Sehested, Henri S. Lichenstein
Journal: Blood (2005)
A homozygous SFTPA1 mutation drives necroptosis of type II alveolar epithelial cells in patients with idiopathic pulmonary fibrosis
Authors: Akio Takezaki, Shin-ichi Tsukumo, Yasuhiro Setoguchi, Julie G. Ledford, Hisatsugu Goto, Kazuyoshi Hosomichi, Hisanori Uehara, Yasuhiko Nishioka, Koji Yasutomo
Journal: The Journal of Experimental Medicine (2019)

Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by scattered fibrotic lesions in the lungs. The pathogenesis and genetic basis of IPF remain poorly understood. Here, we show that a homozygous missense mutation in SFTPA1 caused IPF in a consanguineous Japanese family. The mutation in SFTPA1 disturbed the secretion of SFTPA1 protein. Sftpa1 knock-in (Sftpa1-KI) mice that harbored the same mutation as patients spontaneously developed pulmonary fibrosis that was accelerated by influenza virus infection. Sftpa1-KI mice showed increased necroptosis of alveolar epithelial type II (AEII) cells with phosphorylation of IRE1α leading to JNK-mediated up-regulation of Ripk3. The inhibition of JNK ameliorated pulmonary fibrosis in Sftpa1-KI mice, and overexpression of Ripk3 in Sftpa1-KI mice treated with a JNK inhibitor worsened pulmonary fibrosis. These findings provide new insight into the mechanisms of IPF in which a mutation in SFTPA1 promotes necroptosis of AEII cells through JNK-mediated up-regulation of Ripk3, highlighting the necroptosis pathway as a therapeutic target for IPF.
Effects of Poloxamer 188 on Red Blood Cells Membrane Properties in Sickle Cell Disease
Authors: Barbara Sandor, Mickael Marin, Claudine Lapoumeroulie, Miklos Rabai, Sophie Lefevre, Nathalie Lemonne, Wassim El Nemer, Olivier Francais, Bruno Le Pioufle, Yves Colin Aronovicz, Philippe Connes, Caroline Le Van Kim
Journal: Blood (2015)
Effect of FMS-Like Tyrosine Kinase-3 Mutations on Prognosis in Acute Myeloid Leukemia: A Single Institution Experience between 2000 and 2007.
Authors: Hady A. Ghanem, Dan Jones, Hagop M. Kantarjian, Stefan Faderl, Elihu H. Estey, Sherry Pierce, Susan O’Brien, Jorge Cortes, Farhad Ravandi
Journal: Blood (2007)
ENESTxtnd: Impact Of Nilotinib Dose Re-Escalation In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
Authors: Jeff H. Lipton, Luis Meillon, Vernon Louw, Carolina Pavlovsky, Lee-Yung Shih, Yu Jin, Sandip Acharya, Richard C. Woodman, Timothy P. Hughes, Anna G. Turkina
Journal: Blood (2013)
Supportive Care Only Versus Allogeneic Hematopoietic Cell Transplantation in Patients ≥ 60 Years with De Novo High-Risk MDS.
Authors: Uwe Platzbecker, Jürgen Finke, Rudolf Trenschel, Schaefer-Eckart Kerstin, Martin Bornhauser, Guido Kobbe, Bart L Scott, Gerhard Ehninger, Dietrich Beelen, H. J. Deeg, Ulrich Germing
Journal: Blood (2009)
Prospective Evaluation of the Effect of Deferasirox on Hematologic Response in Transfusion-Dependent Patients with Low-Risk MDS and Iron Overload: The Rythmex Study
Authors: Christian Rose, Olivier Fitoussi, Emmanuel Gyan, Maya Hacini, Shanti Amé, Bernadette Corront, Odile Beyne-Rauzy, Didier Innocent Adiko, Elena-Anca Loppinet, Nadia Ali-Ammar, Eric Wattel, Francois Dreyfus, Stéphane Cheze
Journal: Blood (2016)
Study of Deferiprone or Deferoxamine Versus Combination Therapy in Iron-Loaded Thalassemia Patients in Taiwan.
Authors: Ching-Tien Peng, Kang-Hsi Wu, Chang-Hai Tsai, Chao-Ping Yang, Lin-Yen Wang, Ren-Chin Jang, Chih-Cheng Hsiao
Journal: Blood (2006)
Forty-Year Analysis of Randomized Clinical Trials in Patients with Acute Myeloid Leukemia Treated with Remission Induction Chemotherapy
Authors: Sagar S. Patel, Tomas Radivoyevitch, Aaron T. Gerds, Navneet S. Majhail, Hetty E. Carraway, Anjali S. Advani, Aziz Nazha, Jaroslaw P. Maciejewski, Matt Kalaycio, Mikkael A. Sekeres, Sudipto Mukherjee
Journal: Blood (2016)
Estimation of Eating Disorders Prevalence by Age and Associations With Mortality in a Simulated Nationally Representative US Cohort
Authors: Zachary J. Ward, Patricia Rodriguez, Davene R. Wright, S. Bryn Austin, Michael W. Long
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Eating disorders (EDs) are common psychiatric disorders associated with high mortality. However, data on ED disease dynamics and treatment coverage are sparse. <h3>Objectives</h3> To model the individual-level disease dynamics of ED from birth to age 40 years and to estimate the association of increased treatment coverage with ED-related mortality. <h3>Design, Setting, and Participants</h3> In this decision analytical model study, an individual-level Markov state transition model was empirically calibrated in April 2019 using a Bayesian approach to synthesize available clinical and epidemiologic ED data. The simulation model was calibrated to nationally representative US survey data from 2007 and 2011. A virtual cohort of 100 000 individuals (50 000 [50%] male) was modeled from birth to age 40 years for 4 ED diagnoses: anorexia nervosa, bulimia nervosa, binge eating disorder, and other specified feeding and eating disorders. <h3>Exposures</h3> Age-specific ED incidence and mortality rates and background (all-cause) mortality. <h3>Main Outcomes and Measures</h3> The main outcomes were age-specific 12-month and lifetime ED prevalence and number of deaths per 100 000 general population individuals by age 40 years. The mean and 95% uncertainty intervals (UIs) of 1000 simulations, accounting for stochastic and parameter uncertainty, are reported. <h3>Results</h3> The highest estimated mean annual prevalence of ED occurred at approximately age 21 years for both male individuals (7.4%; 95% UI, 3.5%-11.5%) and female individuals (10.3%; 95% UI, 7.0%-14.2%), with lifetime mean prevalence estimates increasing to 14.3% (95% UI, 9.7%-19.0%) for male individuals and 19.7% (95% UI, 15.8%-23.9%) for female individuals by age 40 years. Ninety-five percent of first-time cases occurred by age 25 years. Current treatment coverage averts an estimated mean of 41.7 deaths per 100 000 people (95% UI, 13.0-82.0 deaths per 100 000 people) by age 40 years, whereas increasing treatment coverage for all patients with ED could avert an estimated mean of 70.5 deaths per 100 000 people by age 40 years (95% UI, 26.0-143.0 deaths per 100 000 people). <h3>Conclusions and Relevance</h3> In this simulation modeling study, the estimated lifetime prevalence of ED was high, with approximately 1 in 7 male and 1 in 5 female individuals having an ED by age 40 years. The initial onset of EDs was highly concentrated during adolescence and young adulthood, suggesting that this is a critical period for prevention efforts. However, the high estimated prevalence of recurring ED later in life highlights the importance of identification and treatment of ED at older ages as well. These findings suggest that increasing treatment coverage could substantially reduce ED-related mortality.
Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers
Authors: Remi Klotz, Amal Thomas, Teng Teng, Sung Min Han, Oihana Iriondo, Lin Li, Sara Restrepo-Vassalli, Alan Wang, Negeen Izadian, Matthew MacKay, Byoung-San Moon, Kevin J. Liu, Sathish Kumar Ganesan, Grace Lee, Diane S. Kang, Charlotte S. Walmsley, Christopher Pinto, Michael F. Press, Wange Lu, Janice Lu, Dejan Juric, Aditya Bardia, James Hicks, Bodour Salhia, Frank Attenello, Andrew D. Smith, Min Yu
Journal: Cancer Discovery (2019)

Abstract Hematogenous metastasis is initiated by a subset of circulating tumor cells (CTC) shed from primary or metastatic tumors into the blood circulation. Thus, CTCs provide a unique patient biopsy resource to decipher the cellular subpopulations that initiate metastasis and their molecular properties. However, one crucial question is whether CTCs derived and expanded ex vivo from patients recapitulate human metastatic disease in an animal model. Here, we show that CTC lines established from patients with breast cancer are capable of generating metastases in mice with a pattern recapitulating most major organs from corresponding patients. Genome-wide sequencing analyses of metastatic variants identified semaphorin 4D as a regulator of tumor cell transmigration through the blood–brain barrier and MYC as a crucial regulator for the adaptation of disseminated tumor cells to the activated brain microenvironment. These data provide the direct experimental evidence of the promising role of CTCs as a prognostic factor for site-specific metastasis. Significance: Interests abound in gaining new knowledge of the physiopathology of brain metastasis. In a direct metastatic tropism analysis, we demonstrated that ex vivo–cultured CTCs from 4 patients with breast cancer showed organotropism, revealing molecular features that allow a subset of CTCs to enter and grow in the brain. This article is highlighted in the In This Issue feature, p. 1
Chromosome Banding Analysis Defines Subclasses of CLL with 13q14 Deletion and Identifies a New Mechanism of Submicroscopic 13q14 Deletions Occurring in the Breakpoint Region of Reciprocal Translocations.
Authors: Claudia Schoch, Frank Dicker, Susanne Schnittger, Wolfgang Kern, Torsten Haferlach
Journal: Blood (2006)
A Phase I Trial of Escalating Dose of the Rapamycin Analog Everolimus in Combination with the Kinase Inhibitor Midostaurin in Patients (pts) with Relapsed, Refractory or Poor Prognosis Acute Myeloid Leukemia (AML)
Authors: Richard M. Stone, Caitlin Driscoll, Ilene Galinsky, Martha Wadleigh, David P. Steensma, David Avigan, Philip C. Amrein, Suiyang Liu, James D. Griffin, Steven L. McAfee, Eyal C. Attar, Karen K. Ballen, Edward Fox, Daniel J. DeAngelo
Journal: Blood (2012)
Long-Term Morbidity and Mortality Experienced By Chronic Myeloid Leukemia (CML) Patients after Allogeneic Hematopoietic Cell Transplantation (HCT) - a Report from BMTSS-2
Authors: Jessica Wu, Yanjun Chen, Lindsey Hageman, Can-Lan Sun, Liton F. Francisco, Emily C. Ness, Mariel Parman, James A. Watson, Daniel J. Weisdorf, David S. Snyder, Philip McGlave, Stephen J. Forman, Mukta Arora, Saro Armenian, Ravi Bhatia, Smita Bhatia
Journal: Blood (2016)
Chronically ill prisoners risk of being transferred without medication because of gaps in care
Authors: Elisabeth Mahase
Journal: BMJ (2019)

Around 120 prisoners with chronic conditions are moved between prisons every day in England, but gaps in care mean many are at risk of going without their medication, says a report.1

The report by the Healthcare Safety Investigation Branch (HSIB)—an independent organisation funded by the government—highlighted the case of Martin, a 43 year old inmate who had multiple seizures after his epilepsy drugs were not transferred with him to a new prison. This was “just one example of a serious outcome when medication was missed.”

The branch has now called for a number of changes to improve the care of patients in prison including integrating the two IT systems used and changing the Care Quality Commission (CQC) inspection process.

The investigation looked …
Cautious Interpretation of Observational Data
Authors: Ricardo Soares-dos-Reis, Silvia Messina
Journal: JAMA Neurology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Myeloid Leukemia Cells With MLL partial Tandem Duplication Are Sensitive To Pharmacological Inhibition Of The H3K79 Methyltransferase DOT1L
Authors: Michael W.M. Kühn, Michael Hadler, Scott R. Daigle, Chun-Wei Chen, Amit U. Sinha, Andrei V. Krivtsov, Edward J. Olhava, Michael A. Caligiuri, James E Bradner, Roy M. Pollock, Scott A. Armstrong
Journal: Blood (2013)
Granulocyte-Derived Cationic Peptides (GDCPs) Present in Leucophoresis Products Enhance Homing of Hematopoietic Stem Cells (HSCs) to SDF-1 Gradient; Potential Implications for Accelerated Recovery of Hematopoiesis After Transplantation of Mobilized Peripheral Blood Stem Cells (PBSC).
Authors: HakMo Lee, Wan Wu, Marcin Wysoczynski, Magdalena Kucia, Mary J. Laughlin, Janina Ratajczak, Mariusz Z Ratajczak
Journal: Blood (2009)
Spliceosome Inhibitor Meayamycin B As a Novel Potential Chemotherapeutic Agent in ALL and AML
Authors: Anna Wojtuszkiewicz, Yehuda G Assaraf, Gerrit Jansen, Kazunori Koide, Robert K. Bressin, Upamanyu Basu, Edwin Sonneveld, Elisa Giovannetti, Gertjan Kaspers, Jacqueline Cloos
Journal: Blood (2014)
Recurrent Mutations in Focal Adhesion Genes Including the RhoA Signaling Axis Are a Defining Feature of Germinal Center (GC) Derived B Cell Lymphomas and Promote Aberrant Migration and Cellular Adhesion within the GC Niche
Authors: Jane Healy, Rachel E Rempel, Andrea B. Moffitt, Nicholas Davis, Jenny Zhang, Cassandra Love, Jennifer R Shingleton, Sandeep Dave
Journal: Blood (2015)
Allogeneic Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies Not in Remission: The Anti-Tumor Effect of Reduced-Intensity Conditioning Is Comparable to That of Conventional Myeloablative Conditioning.
Authors: Dai Maruyama, Takahiro Fukuda, Ruri Kato, Satoshi Yamasaki, Eiji Usui, Yuriko Morita, Sung-Won Kim, Shin-ichiro Mori, Ryuji Tanosaki, Kinuko Tajima, Yuji Heike, Atsushi Makimoto, Kensei Tobinai, Yoichi Takaue
Journal: Blood (2005)
The Aurora-Kinase Inhibitor R763/AS703569 Exerts Major Growth-Inhibitory and Apoptosis-Inducing Effects on Neoplastic Mast Cells
Authors: Barbara Peter, Harald Herrmann, Karoline V. Gleixner, Emir Hadzijusufovic, Sylvia Laffer, Karina Schuch, Winfried Pickl, Samantha M. Sarno, Michael Willmann, Peter Valent
Journal: Blood (2010)
Genome-Wide Profiling of Epigenetic and Transcription Factor Regulation In Human Macrophage Differentiation
Authors: Thu-Hang Pham, Monika Lichtinger, Chris Benner, Sabine Pape, Lucia Schwarzfischer, Maja Klug, Andreas Gogol-Doering, Yuhui Hu, Reinhard Andreesen, Wei Chen, Michael Rehli
Journal: Blood (2010)
High Frequency of Circulating Endothelial Colony Forming Cells (ECFCs) in Myeloproliferative Neoplasms (MPNs) Is Associated with Diagnosis of Prefibrotic Myelofibrosis, History of Splanchnic Vein Thrombosis, and Vascular Splenomegaly.
Authors: Vittorio Rosti, Elisa Bonetti, Gaetano Bergamaschi, Rita Campanelli, Elisabetta Gattoni, Sonia Lo Po, Umberto Magrini, Margherita Massa, Alessandro Vannucchi, Gianluca Viarengo, Paola Guglielmelli, Massimo Primignani, Giovanni Barosi
Journal: Blood (2009)
Molecular Detection of Minimal Residual Disease Provides the Most Powerful Independent Prognostic Factor Irrespective of Clonal Architecture in Nucleophosmin (NPM1) Mutant Acute Myeloid Leukemia
Authors: Adam Ivey, Robert K Hills, Michael A Simpson, Jelena V Jovanovic, Amanda F Gilkes, Yashma Patel, Neesa Bhudia, Hassan Farah, Joanne Mason, Kerry Wall, Susanna Akiki, Ellen Solomon, Frank McCaughan, David C Linch, Rosemary E Gale, Paresh Vyas, Sylvie D Freeman, Nigel Russell, Alan K. Burnett, David Grimwade
Journal: Blood (2014)